ArticleClinical and molecular hepatology2025
Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823].
Sun Young Yim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.